MIAMI WIRE   |

April 16, 2024
Search
Close this search box.

New York Cryogen Unveils Ambitious Plans for Expansion, Insurance Integration, and Cutting-Edge Innovations

New York Cryogen
Photo Courtesy: Gregory Papageorge

In a bold leap into the future, New York Cryogen, a trailblazer in the healthcare industry, is set to redefine the landscape of cryotherapy and pain management. This comprehensive exploration unveils the company’s ambitious plans for expansion, a groundbreaking integration with insurance providers, and a glimpse into upcoming innovations that promise to revolutionize the field. As readers embark on this informative journey, they will witness not just the evolution of a company but a transformative shift in the way we approach pain management and well-being.

New York Cryogen, founded by visionary entrepreneur Gregory Papageorge, is on a trajectory of unprecedented growth and expansion. The company, which started its journey with a singular focus on high-pressure medical cryotherapy, is now poised to broaden its horizons and reach new milestones in the healthcare industry.

Geographical Expansion

New York Cryogen’s first strategic move is geographical expansion. With a robust presence in several states, the company is eyeing a nationwide reach, bringing its revolutionary cryotherapy solutions to medical facilities, clinics, and wellness centers across the country.

International Footprint

Beyond national borders, New York Cryogen is gearing up for an international footprint. The vision is to introduce high-pressure medical cryotherapy to a global audience, transcending boundaries to make this transformative technology accessible on a global scale.

Canadian Endeavor

As part of its expansion plans, New York Cryogen is setting its sights on Canada. With a commitment to establishing a strong presence in the country, the company aims to introduce its groundbreaking cryotherapy solutions to the Canadian healthcare landscape.

One of the most groundbreaking announcements from New York Cryogen is its integration with insurance providers. In a pioneering move, the company has achieved recognition and approval from the American Medical Association (AMA) with exclusive CPT billing codes. This marks the first instance in the history of cryotherapy where a company can accept healthcare insurance for its treatments.

Affordable Cryotherapy

Integration with insurance providers opens the doors for more individuals to access high-pressure medical cryotherapy. This move democratizes pain management, making it an affordable and viable option for a broader demographic.

Opioid-Sparing Option

New York Cryogen’s integration with insurance positions high-pressure cryotherapy as an opioid-sparing option for those suffering from chronic and acute pain. This groundbreaking approach aligns with the global effort to combat the opioid epidemic.

Widespread Recognition

AMA’s recognition and approval not only validate the efficacy of high-pressure medical cryotherapy but also pave the way for widespread recognition within the medical community. New York Cryogen is now at the forefront, leading the charge for insurance-supported cryotherapy treatments.

The heartbeat of New York Cryogen lies in its commitment to innovation. The company is set to unveil groundbreaking devices that will further cement its position as a leader in cryotherapy and pain management.

AC-130 Viper

The AC-130 Viper is poised to be the first-of-its-kind in the world. This innovative medical device, developed by New York Cryogen, promises to take cryotherapy to new heights. With cutting-edge technology and unrivaled efficiency, the AC-130 Viper is set to be a game-changer in the field of pain management.

Portable Handheld Device

New York Cryogen is on the brink of releasing its first portable handheld device. Once launched, this device will enable individuals to access high-pressure cryotherapy treatments in the comfort of their homes. Moreover, with plans to accept healthcare insurance for this treatment, New York Cryogen is paving the way for a paradigm shift in the accessibility of cryotherapy.

Nationalization in 2023

Looking ahead, New York Cryogen has set its sights on nationalization. By the year 2023, the company aims to nationalize its high-pressure cryotherapy treatments, making them accessible to individuals across the United States, including Hawaii and Puerto Rico.

At the helm of this groundbreaking journey is Gregory Papageorge, the visionary founder of New York Cryogen. With 24 years of experience in healthcare sales, including the last 15 years in medical devices specializing in complex spine, Papageorge’s vision is not just about building a successful company but about shaping the future of cryotherapy and pain management.

Ongoing Clinical Trials

New York Cryogen’s commitment to excellence is evident in its ongoing clinical trials. With over 6,000 procedures personally performed by Gregory Papageorge in less than two years, the company is dedicated to ensuring the safety, efficacy, and transformative potential of its cryotherapy solutions.

AMA Recognition

The American Medical Association’s recognition and endorsement of New York Cryogen’s high-pressure cryotherapy treatments stand as a testament to the company’s commitment to achieving the highest standards in the field. Papageorge’s vision of creating an innovative and accredited approach to pain management is now a reality.

Leadership in Cryotherapy

Gregory Papageorge envisions New York Cryogen not just as a company but as a leader in cryotherapy. With an emphasis on affordability, accessibility, and continuous innovation, he is spearheading a movement that has the potential to change the face of pain management globally.

Stay updated on their groundbreaking innovations by following New York Cryogen on Instagram (@newyorkcryogen) and Facebook (New York Cryogen). Visit their website at www.nycryogen.comwww.ac130viper.com to learn more about their products and services.

Published by: Nelly Chavez

Share this article

(Ambassador)

This article features branded content from a third party. Opinions in this article do not reflect the opinions and beliefs of Miami Wire.